Fischer Medical Ventures Strengthens Strategic Partnership with Nanyang Biologics to Advance AI-Driven Life Sciences Research in India
Mumbai : Fischer Medical Ventures Limited (FMVL) highlighted its strategic partnership with Nanyang Biologics, reinforcing its commitment to bringing advanced AI-powered molecular research technologies to India and supporting the country’s pharmaceutical and life sciences ecosystem.
Through this partnership, Fischer Medical Ventures aims to introduce AI-enabled molecular research capabilities to India, foster association with pharmaceutical companies, biotechnology innovators, academic institutions and research organisations, and accelerate the discovery of novel therapeutic molecules. By combining artificial intelligence with India’s scientific expertise and rich botanical and Ayurvedic heritage, the partnership seeks to support evidence-based therapeutic innovation, subject to scientific validation and regulatory approvals.
Fischer Medical Ventures serves as the exclusive distributor in India for selected NYB technologies and scientifically developed plant-based nutraceutical products, subject to applicable regulatory approvals. A key part of the collaboration is Vecura, Nanyang Biologics’ advanced molecular research platform that enables researchers to simulate molecular behavior, predict material properties and conduct high-throughput computational analysis to accelerate research and therapeutic discovery.
Leadership Commentary
Mr. Ravindran Govindan, Chairman, Fischer Medical Ventures Limited, said:
“NYB.AI’s recognition at NVIDIA GTC Taiwan 2026 validates the strength of the technology developed by our strategic partner, Nanyang Biologics. We are proud to work alongside an organisation that is helping redefine AI-driven molecular research, and we look forward to introducing these capabilities to India’s scientific and pharmaceutical community.”
He added:
“India possesses exceptional scientific talent, a globally respected pharmaceutical industry and a rich heritage of botanical knowledge. By combining these strengths with advanced artificial intelligence, we have an opportunity to accelerate innovation, strengthen research capabilities and contribute to the discovery of new therapies that address unmet medical needs.”
Ms. Svetlana Rao Raviwada, Whole-Time Executive Director, Fischer Medical Ventures Limited, said:
“Our partnership with Nanyang Biologics is about more than bringing advanced technology to India; it is about building an AI-enabled life sciences ecosystem that strengthens collaboration between academia, research institutions and the pharmaceutical industry. Through advanced platforms such as Vecura, we aim to equip Indian researchers with world-class AI-powered molecular research capabilities that can accelerate scientific discovery and foster innovation across the healthcare and life sciences sectors.”
As an international milestone, Nanyang Biologics’ AI-powered molecular research platform, NYB.AI, was recently featured in the opening showcase at NVIDIA GTC Taiwan 2026, reflecting the global recognition of the technology supporting this strategic partnership.
